David Sallman, MD

TP53 mutations represent a critical high-risk factor across myeloid diseases, necessitating immediate transplant referral as the only curative option due to the limited durability of current standard therapies such as venetoclax and hypomethylating agents.

Dr David Sallman tailors venetoclax dosing based on transplant candidacy, using 21-day induction for transplant-eligible patients followed by rapid tapering upon response.

A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David Sallman, MD. Proceeding directly to transplant in patients with TP53-mutated disease may lead to optimal outcomes.

David Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.